Using ustekinumab to prevent graft versus host disease after stem cell transplants
Ustekinumab for Graft versus Host Disease Prevention (IND 144540)
This study is looking at whether a medication called ustekinumab can help prevent graft versus host disease (GVHD) in people getting stem cell transplants, especially from unrelated donors, to improve their chances of recovery and overall well-being.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10681200 on NIH RePORTER |
What this research studies
This research investigates the use of ustekinumab, a targeted therapy, to prevent graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Current treatments are not effective enough, particularly for those receiving transplants from unrelated donors. The study will involve a randomized, double-blinded, placebo-controlled trial to compare the effects of ustekinumab against a placebo, both alongside standard immune suppression. The goal is to improve the survival rates and quality of life for patients by reducing the incidence of acute GVHD.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing allogeneic hematopoietic cell transplantation, particularly those receiving transplants from unrelated donors.
Not a fit: Patients who are not undergoing allogeneic hematopoietic cell transplantation or those who have already developed graft versus host disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the occurrence of graft versus host disease, leading to better survival rates and improved quality of life for transplant recipients.
How similar studies have performed: Previous studies have shown promising results with similar approaches, indicating that targeting IL-12/23p40 may effectively prevent GVHD.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Lee, Stephanie J — Fred Hutchinson Cancer Center
- Study coordinator: Lee, Stephanie J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.